Treatment strategy of minodronate in osteoporotic patients with rheumatoid arthritis
Not Applicable
- Conditions
- Osteoprotic patients with rheumatoid arthritis
- Registration Number
- JPRN-UMIN000022364
- Lead Sponsor
- Department of Orthopaedic Surgery Shinshu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
1. The patients who are allergic to minodronate or eldecalcitol 2. The patients with hypercalcemia before treatment 3. The patients whom we judge as inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Value changes of bone mineral density (lumber as well as bilateral proximal hip) before treatment and at 24 months after treatment
- Secondary Outcome Measures
Name Time Method Frequencies of adverse effects (at 6, 12, and 24 months after treatment) Value chanes of the following at 6, 12, and 24 months after treatment 1. Bone mineral density (lumber as well as bilateral proximal hip) values 2. Values of bone turnover markers 3. Values of serum vitamin D 4. Values of serum PTH